HAMILTON, Bermuda, Oct. 26, 2015 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, will announce its second quarter 2015 financial results after the close of the U.S. financial markets on November 2, 2015 and members of its senior management team will host a conference call and webcast at 4:30 p.m. ET that day.
To participate in the call, please dial (866)-807-9684 (U.S. and Canada) or (412)-317-5415 (International) and ask to be connected to the “Axovant Call”. Please dial in 10 minutes prior to the scheduled start time.
A replay of the call will be available from one hour after the end of the live call on November 2, 2015 until 11:59 p.m. ET on November 16, 2015 by dialing (877)-344-7529 (U.S.) or (855)-669-9658 (Canada) or (412)-317-0088 (International) and the passcode 10075025.
A simultaneous webcast can be accessed by visiting the Investors section of www.axovant.com and selecting Events and Presentations. In addition, a replay of the webcast will be available until 11:59 p.m. ET on December 2, 2015. The replay can be accessed by clicking on “Events” in the Investor Relations section of the website.
About Axovant
Axovant Sciences Ltd. is a leading clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of dementia, a condition characterized by significant decline in mental capacity and impaired daily function. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, behavioral and functional components of dementia, including Alzheimer’s disease.
Logo - http://photos.prnewswire.com/prnh/20150629/226455LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/axovant-sciences-to-announce-second-quarter-2015-financial-results-on-november-2-2015-300166206.html
SOURCE Axovant Sciences Ltd.
Help employers find you! Check out all the jobs and post your resume.
